Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
| MarketCap | 458M |
|---|---|
| PE Ratio | |
| PEG Ratio | -0.8 |
| P/B | 2.5 |
| P/S (ttm) | 79.4 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 5% |
| Held by Institutions % | 76% |
| 1 Day Vol Adjusted Return | -1.7 |
| 1 Month Vol Adjusted Return | 1.1 |
| 3 Month Vol Adjusted Return | 4.2 |
| 6 Month Vol Adjusted Return | 13.6 |
| 20 Days SMA Price ZScore | -0.1 |
| 50 Days SMA Price ZScore | 0.2 |
| 12 -26 Days PPO | 3.6 |
| 1 Month Average Short Volume Ratio | 38.2 |
| 1 Day Volume Change ZScore | -0.7 |
| 1 Month Daily Vol | 5.3 |
Stock news
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Virtual SVB Leerink 10th Annual Global Healthcare ConferencePresentation on Thursday, February 25, 2021 at 10:40 a.m. ET. Virtual H.C. Wainwright Global Life Sciences ConferencePrerec...
The big shareholder groups in Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) have power over the company. Generally...
CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purchase...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses pay...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Fulcrum. In addition, Fulcrum expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its co...
Owen Wallace to Transition to Scientific Advisory BoardCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Christopher Moxham, Ph.D., has been promoted to the role of chief scientific officer. In this role, Dr. Moxham will oversee the organization’s full range of drug discovery and translational science resea...
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference. A webcast will be available on-demand on Monday, January 11, 2021 at 6:00 a.m. ET through the H.C. Wainwright conference portal and on the Investor Relation...
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]